BRAF and melanoma: A previous study has revealed that an increase in the neural crest stem–like cell gene expression signature, a marker for the DTP cell population, could be only detected in some of the patients (20%) with partial response to targeted therapy in BRAF-mutant melanoma but was absent from patients with progressive disease and/or stable disease (17).